Targeting soluble tumor necrosis factor as a potential intervention to lower risk for late-onset Alzheimer’s disease associated with obesity, metabolic syndrome, and type 2 diabetes. Here, TNF is linked to obesity due to melanocortin 4 receptor deficiency.